Vaccines are considered the best approach for countering the COVID-19 pandemic. In this study, we compared early side effects associated with vaccination with the Sinopharm and Pfizer–BioNTech COVID-19 vaccines. Participants of this observational cohort were interviewed based on semi-structured telephone interviews, with enquiries about side effects that developed after vaccination with each dose of these vaccines. Overall, 1004 participants were enrolled, of which 51.1% received Sinopharm vaccine and 48.9% received the Pfizer–BioNTech vaccine. After the first dose, 46.3% of participants had an adverse reaction, with injection site pain most commonly being reported (33.2%). Participants who received the Pfizer–BioNTech vaccine had significantly higher frequencies of all types of adverse reactions ( p < 0.01), with no significant differences in the duration of adverse reactions between the two vaccines. Regarding the second dose, 48.6% of participants had adverse reactions, with injection site pain being most commonly reported (29%). Those who received the Pfizer vaccine reported higher frequencies of all adverse reactions ( p < 0.01). However, a longer duration of adverse reactions was seen among Sinopharm vaccine recipients as compared to Pfizer–BioNTech vaccine recipients ( p = 0.01). In conclusion, early adverse effects are reported following all types of vaccines but these are more likely to be encountered following the administration of new-generation vaccines. These side effects are mostly mild and treatable.
【저자키워드】 COVID-19, Vaccine, pandemic, Sinopharm, Pfizer–BioNTech, 【초록키워드】 vaccination, Vaccines, COVID-19 pandemic, Pfizer, Adverse reactions, Cohort, COVID-19 vaccines, Mild, administration, Frequency, dose, Adverse reaction, adverse effect, Side effect, no significant difference, second dose, first dose, participant, recipient, Pfizer–BioNTech, approach, injection site pain, enrolled, reported, significantly higher, treatable, 【제목키워드】 telephone, Qualitative, assessment, Adverse, interview, Pfizer–BioNTech, Effect,